Get started
Work

Supplementary Table S5 from A Phase II Study of Atezolizumab, Pertuzumab, and High-Dose Trastuzumab for Central Nervous System Metastases in Patients with HER2-Positive Breast Cancer

Year: 2024
Type: supplementary-materials
Abstract: Supplementary Table S5. Complete details on treatment administered during study including dose delays, modifications, and holds.
DOI: 10.1158/1078-0432.27434386
Authors: Antonio Giordano, Priya U. Kumthekar, Qingchun Jin, Busem Binboga Kurt, Siyang Ren, Tianyu Li, Jose Pablo Leone, Elizabeth A. Mittendorf, Alyssa M. Pereslete, Laura Sharp, Raechel Davis, Molly DiLullo, Nabihah Tayob, Erica L. Mayer, Eric P. Winer, Sara M. Tolaney, Nancy U. Lin
Language: English
Field: Medicine
Open Access status: gold
OpenAlex ID: W4403989242
Cites:
Cited by:
Related to: 10